(D-ARG1,D-TRP7·9,LEU11)-SUBSTANCE P
| 中文名称 | (D-ARG1,D-TRP7·9,LEU11)-SUBSTANCE P |
|---|---|
| 中文同义词 | D-ARG1,D-TRP7,9,LEU11]神经肽P物质;化合物 T20413;D-精氨酸1,D-色氨酸7,9,亮氨酸11]P物质;化合物 Spantide I;Spantide I TFA【CAS:91224-37-2】【规格:1mg】【纯度:98%】;Spantide I TFA【CAS：91224-37-2】【规格：1mg】【纯度：98%】 |
| 英文名称 | D-ARG-PRO-LYS-PRO-GLN-GLN-D-TRP-PHE-D-TRP-LEU-LEU-NH2 HYDROCHLORIDE |
| 英文同义词 | [D-ARG1,D-TRP7,9,LEU11]-SUBSTANCE P HYDROCHLORIDE;(D-ARG1,D-TRP7,9,LEU11)-SUBSTANCE P;D-ARG-PRO-LYS-PRO-GLN-GLN-D-TRP-PHE-D-TRP-LEU-LEU-NH2;D-ARG-PRO-LYS-PRO-GLN-GLN-D-TRP-PHE-D-TRP-LEU-LEU-NH2 HYDROCHLORIDE;H-D-ARG-PRO-LYS-PRO-GLN-GLN-D-TRP-PHE-D-TRP-LEU-LEU-NH2;(D-arg1,D-trp7,9,leu11)-substance P*acetate;D-ARG1,D-TRP7,9,LEU11]-SUBSTANCE P (SPANTIDE);M.W. 1497.80 C75H108N20O13 |
| CAS号 | 91224-37-2 |
| 分子式 | C75H108N20O13 |
| 分子量 | 1497.79 |
| EINECS号 | |
| 相关类别 | 标准品;Tachykinin receptor |
| Mol文件 | 91224-37-2.mol |
| 结构式 |  |
(D-ARG1,D-TRP7·9,LEU11)-SUBSTANCE P 性质
| 密度 | 1.43±0.1 g/cm3(Predicted) |
|---|---|
| 储存条件 | −20°C |
| 形态 | 粉末 |
| 酸度系数(pKa) | 13.31±0.20(Predicted) |
| 颜色 | 白色至米白色 |
| 水溶解性 | Soluble to 1 mg/ml in water |
Spantide I 是substance P 的类似物，是选择性的神经激肽-1 受体 (NK1 receptor) 的拮抗剂，其对NK1 和 NK2 受体的 Ki 值分别为 230 nM 和 8150 nM。Spantide I 可减少感染角膜的1型细胞因子和增强2型细胞因子 IL-10，从而显著减少角膜穿孔。
|
NK1 230 nM (Ki) |
NK2 8150 nM (Ki) |
Spantide I (50 and 100 nM perfused through the cerebral ventricles) causes a complete respiratory arrest in all of the examined animals.
Spantide I (36 μg/mouse, ip daily) significantly decreases the number of perforated corneas, bacterial counts, and PMNs. Spantide I also downregulates the mRNA levels for type I cytokines (e.g., IFN-γ) as well as MIP-2, IL-6, TNF-α, and IL-1β.
| Animal Model: | Female, 8-week-old C57BL/6 (B6) and BALB/c mice. |
| Dosage: | 36 μg/mouse. |
| Administration: | IP on days -1 and 0 (day of infection) and daily through 5 days pi (post infection). |
| Result: |
At 3 and 5 days pi, compound-treated mice had significantly less severe ocular disease than did the PBS-treated mice.
Contained significantly fewer PMNs than the corneas of PBS-treated mice at 3 and 5 days pi. Significantly reduced levels of corneal TNF-α mRNA at 3 and 5 days pi. Significantly reduced the level of IL-18 mRNA at 1 day pi. |
安全信息
| WGK Germany | 3 |
|---|
| 提供商 | 语言 |
|---|---|
|
英文
|
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2025/12/22 | HY-P1194 | (D-ARG1,D-TRP7·9,LEU11)-SUBSTANCE P Spantide I | 91224-37-2 | 1 mg | 550元 |
| 2025/12/22 | HY-P1194 | (D-ARG1,D-TRP7·9,LEU11)-SUBSTANCE P Spantide I | 91224-37-2 | 5 mg | 1650元 |